Mifepristone inhibits MPA- and FGF2-induced mammary tumor growth but not FGF2-induced mammary hyperplasia

Medicina

Volumn 70, Issue 6, 2010, Pages 529-532

  Cerliani, Juan P ^a   Giulianelli, Sebastian ^a   Sahores, Ana ^a   Wargon, Victoria ^a   Gongora, Adrian ^a   Baldi, Alberto ^a   Molinolo, Alfredo ^b   Lamb, Caroline A ^a   Lanari, Claudia ^a  

^a Universidad Nacional de Río Cuarto Consejo Nacional de Investigaciones Científicas y Técnicas   (Argentina)

^b NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

Breast cancer; FGF2; Mammary carcinomas; Mammary gland; Progestins; RU486

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; PROGESTERONE RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST HYPERPLASIA; BREAST TUMOR; CANCER INHIBITION; FEMALE; MOUSE; NONHUMAN; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VOLUME;

ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLAST GROWTH FACTOR 2; HORMONE ANTAGONISTS; HYPERPLASIA; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; MEDROXYPROGESTERONE ACETATE; MICE; MIFEPRISTONE;

EID: 78650630990     PISSN: 00257680     EISSN: 16699106     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Jordan VC, Brodie AM. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 2007; 72: 7-25.
2. Lange CA, Sartorius CA, Abdel-Hafiz H et al. Progesterone receptor action: translating studies in breast cancer models to clinical insights. Adv Exp Med Biol 2008; 630: 94-111.
3. Normanno N, Di Maio M, De Maio E et al. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 2005; 12: 721-47.
4. Schwertfeger KL. Fibroblast growth factors in development and cancer: insights from the mammary and prostate glands. Curr Drug Targets 2009; 10: 632-44.
5. Hynes NE, Dey JH. Potential for targeting the fibroblast growth factor receptors in breast cancer. Cancer Res 2010; 70: 5199-202.
6. Hunter DJ, Kraft P, Jacobs KB et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 2007; 39: 870-4.
7. Bane AL, Pinnaduwage D, Colby S et al. Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors. Breast Cancer Res Treat 2009; 117: 183-91.
8. Lanari C, Lamb CA, Fabris VT et al. The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. Endocr Relat Cancer 2009; 16: 333-50.
9. Giulianelli S, Cerliani JP, Lamb CA et al. Carcinoma-associated fibroblasts activate progesterone receptors and induce hormone independent mammary tumor growth: A role for the FGF-2/FGFR-2 axis. Int J Cancer 2008; 123: 2518-31.
10. Montero GG, Vanzulli SI, Cerliani JP et al. Association of estrogen receptor alpha and progesterone receptor A expression with hormonal mammary carcinogenesis: role of the host microenvironment. Breast Cancer Res 2007; 9: R22.
11. Molinolo A, Simian M, Vanzulli S et al. Involvement of EGF in medroxyprogesterone acetate (MPA)-induced mammary gland hyperplasia and its role in MPA-induced mammary tumors in BALB/c mice. Cancer Lett 1998; 126: 49-57.
12. Lu P, Ewald AJ, Martin GR, Werb Z. Genetic mosaic analysis reveals FGF receptor 2 function in terminal end buds during mammary gland branching morphogenesis. Dev Biol 2008; 321: 77-87.
13. Horwitz KB, Tung L, Takimoto GS. Novel mechanisms of antiprogestin action. Acta Oncol 1996; 35: 129-40.
14. Poole AJ, Li Y, Kim Y et al. Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 2006; 314: 1467-70.
15. Giulianelli S, Herschkowitz JI, Patel V et al. MPA-induced gene expression and stromal and parenchymal gene expression profiles in luminal murine mammary carcinomas with different hormonal requirements. Breast Cancer Res Treat 2010 (in press).
16. Lanari C, Lamb CA, Cerliani JP et al. Mammary carcinoma associated fibroblasts as key players in the acquisition of hormone independence. Interaction between progesterone receptors and Fibroblast Growth Factor Receptor 2. Medicina (Buenos Aires) 2007; 67 (Supl. II): 65-9.